Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

is and a growing percentage throughout the course of the

disease.

-- American Society of Hematology (ASH) Meeting -- Numerous VELCADE

abstracts are expected to be featured at the ASH meeting in December

2007. These abstracts may include data from two large, randomized

Phase III trials in patients with newly diagnosed MM. Data may also be

presented on additional VELCADE based combinations in front-line MM and

Non-Hodgkin's Lymphoma (NHL).

Clinical Pipeline Highlights

In addition to VELCADE, the Company continues to advance ten novel molecules in the areas of cancer and inflammatory diseases. Recent progress included the following:

-- MLN0002 - The Company completed enrollment in the bridging trials

designed to evaluate the safety, tolerability, pharmacokinetics and

pharmacodynamics of this novel antibody to the target alpha 4 beta 7,

derived from a new commercially scalable cell line. The Company is

tracking toward pivotal trials with MLN0002 in ulcerative colitis and

Crohn's disease.

-- MLN3897 - The Company is on track to announce top-line results for this

novel CCR1 inhibitor by year end from a 191-patient Phase II proof-of-

concept trial in rheumatoid arthritis.

-- MLN4924 - In October 2007, the Company presented data on this

Millennium-discovered molecule and target at the European Organization

for Research and Treatment of Cancer (EORTC) meeting. Data for this

inhibitor of the Nedd8-activating enzyme showed the molecule

significantly inhibited tumor growth in xenograft models for colorectal

cancer and several types of lymphoma. MLN4924 is expected to enter

Phase I trials in early 2008.

Conference Call and Presentation Reminder

Dr. Dunsire and members of the Millennium leadership team will present additional details on these results this m
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , ... By Susan Catalano, Ph.D., Acumen Pharmaceuticals, Sylvia de Bruin, Joe Bosworth, ... Corporation, , 1311 Orleans Drive, Sunnyvale, CA 94089. , ... G-protein coupled receptors (GPCRs are the largest class of pharmaceutical ...
... and Ario de Marco , EMBL Protein Expression ... , Introduction ,Immobilized Metal ion Affinity ... that allows the fast separation of His-tagged proteins ... resins but all of them show some affinity ...
... , ,,Application Guide, ,I. Description ,II. Product ... User ,IV. Protocol for Extraction of DNA from ... from Plant ,VI. Quantification of Amplified Products ... References , Contact Information , , ,Application Guide, , ...
Cached Biology Technology:High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 2High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 3High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 4High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 5High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 6High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 7High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 8High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 9High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 10High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 11Double-Affinity Purification of GST-His Tagged Proteins Using Vivapure 8-to-96 Well Cobalt-Chelate Kit 2Double-Affinity Purification of GST-His Tagged Proteins Using Vivapure 8-to-96 Well Cobalt-Chelate Kit 3Double-Affinity Purification of GST-His Tagged Proteins Using Vivapure 8-to-96 Well Cobalt-Chelate Kit 4Protocol for GenomePlex Whole Genome Amplification from Plant 2Protocol for GenomePlex Whole Genome Amplification from Plant 3Protocol for GenomePlex Whole Genome Amplification from Plant 4Protocol for GenomePlex Whole Genome Amplification from Plant 5Protocol for GenomePlex Whole Genome Amplification from Plant 6
(Date:4/17/2014)... on a novel method to help kidney stone ... effective treatment possible., Kidney stones represent a major ... If left untreated, apart from being particularly painful, ... complications. In many patients treated successfully, stone recurrence ... pathological approach to diagnosis and treatment needs to ...
(Date:4/17/2014)... have detected new early-warning signs of the potential loss ... far-reaching implications for the diagnosis and treatment of diabetic ... Americans. , "We had not expected to see such ... said Ann Elsner, professor and associate dean in the ... study. "We set out to study the early signs, ...
(Date:4/17/2014)... immune system may fight cancers and viral infections. The ... treat illness. , The research, in mice, suggests that ... specialized squads of defenders that patrol only one ... the body. , Scientists at Washington University School of ... skin and uterus each has dedicated immune cells, which ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Some immune cells defend only 1 organ 2
... in Plant Science Automated conserved ... promoter evolution among grasses Within the genome of ... undergo little change in position and sequence over millions of ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), are ...
... Investigators at Rollins School of Public Health at Emory ... Technology, have received a $4 million grant over four ... (Health and Exposome Research Center: Understanding Lifetime Exposures). The ... the United States. The HERCULES Center is ...
... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. The project is one of ...
Cached Biology News:Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... Microarrays designed for genome-wide microRNA expression profiling ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... microRNA Expression Profiling Service. Probe ... all known cow microRNAs (108 unique mature ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Viruses microRNA Microarray contains all known ...
...
... The Agilent 6850 Networked GC is an excellent ... footprint of a standard dual-channel GC, this one-channel ... GCs in the space of one. You get ... routine GC analyses in an instrument that has ...
Biology Products: